{"id":"W4406238848","doi":"10.1016/j.ejca.2024.115146","title":"Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Regeneron Pharmaceuticals","keywords":"Cervical cancer; Medicine; Phase (matter); Oncology; Internal medicine; Cancer; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002016203,0.0002948859,0.001370559,0.00107064,0.00004979757,0.0000336747,0.0005007907,0.00007124612,0.001302572],"category_scores_gemma":[0.0002575395,0.000189208,0.0006851358,0.002984633,0.0001026461,0.0001042312,0.00009210709,0.0008671083,0.000003939807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005291603,"about_ca_system_score_gemma":0.0005772612,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007769282,"about_ca_topic_score_gemma":0.001289798,"domain_scores_codex":[0.995593,0.0009993828,0.001683436,0.0003385464,0.0009755,0.0004101974],"domain_scores_gemma":[0.9981313,0.0004203677,0.0006033783,0.0003576913,0.0003013633,0.0001858549],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4630492,0.009998897,0.1316804,0.0003532862,0.007128099,0.002120463,0.003545793,0.001376109,0.0006865836,0.0005540837,0.00377233,0.3757347],"study_design_scores_gemma":[0.415967,0.005391573,0.5276638,0.001264488,0.005914702,0.00001729999,0.0005489892,0.0004565429,0.0003512429,0.000116828,0.04191682,0.000390733],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9747874,0.009234169,0.00008626429,0.005263365,0.001408327,0.0005091686,0.00007673426,0.000008655498,0.008625897],"genre_scores_gemma":[0.9953163,0.002584707,0.0000472262,0.0009176081,0.0007654861,0.00002393494,0.00001497107,0.00002264892,0.0003071006],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3959834,"threshold_uncertainty_score":0.9996104,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05234366053193121,"score_gpt":0.3867220006093425,"score_spread":0.3343783400774113,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}